Section 07 · contact
Write to the desk.
Corrections, citation tips, and additions to the reading list are welcome. We can't answer medical questions and we are not a vendor.
What we read
We read corrections, citation tips, suggestions of papers we should add to the reading list, notes on places where the language could be clearer, and feedback from researchers working in the GHRH-analog literature. If we got a study summary wrong — wrong n, wrong dose, wrong endpoint — we want to know, and we will correct it.
We are most interested in: newly indexed papers in the GHRH-analog class, corrections to published trial summaries, additional context on the 2008 Geref withdrawal, and pointers to forthcoming 2025-2026 trials we should be tracking.
What we cannot help with
We cannot answer medical questions. We are not clinicians, we have no clinical staff, and we cannot provide diagnosis, treatment recommendations, or dosing advice for any reader. If you have a medical question about growth hormone deficiency, growth hormone-axis testing, or any other endocrine condition, please ask a licensed physician.
We are also not a vendor channel. We do not sell sermorelin, we do not refer readers to vendors, we do not maintain affiliate relationships with any compounding pharmacy or peptide supplier, and we cannot tell you where to obtain sermorelin. Inquiries asking for product, pricing, or vendor referrals will not be answered.
How to reach us
The editorial desk reads email at desk@sermorelinmd.com. We try to acknowledge every legitimate correction or citation tip, though we cannot guarantee a response time. Form submissions through the contact field below are routed to the same inbox.
The content on this site is editorial. Sermorelin is a peptide compound with no current FDA-approved finished drug presentation in the U.S. The material on this site is for research-reading purposes only and is not medical advice.